The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Am J Psychiatry 165:262-a-263, February 2008
doi: 10.1176/appi.ajp.2007.07091462
© 2008 American Psychiatric Association
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by BURBECK, R.
* Articles by McDONALD, L.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by BURBECK, R.
* Articles by McDONALD, L.

Letter to the Editor

Antidepressants in the Postpartum Period: Additional Considerations

RACHEL BURBECK, M.Sc., STEPHEN PILLING, M.Sc., DAVE TOMSON, M.D., and LIZ McDONALD, M.D.
London, United Kingdom

To The Editor: We read with interest the article by Jennifer L. Payne, M.D., published in the September 2007 issue of the Journal, on practical considerations of antidepressant use postnatally (1). However, as developers of the United Kingdom National Clinical Guideline on Antenatal and Postnatal Mental Health (2), we found the article to be inaccurate in several respects.

We agree that maintaining drugs started during pregnancy in the postnatal period is appropriate but feel that this means that paroxetine, although virtually undetectable in breast milk, should not be given to a woman who wishes to breast-feed, given the concern over its safety in pregnancy (3, 4) and the possible difficulties on withdrawal.

While monitoring a breastfed infant is important, the additional point should be made that neonates whose mothers took antidepressants during pregnancy should also be monitored both for symptoms of withdrawal from the drug and for serotonergic toxicity syndrome (the symptoms are similar) (2, 5).

After a careful review of the available data, we concluded that "indicated" prevention may benefit women with subthreshold symptoms of depression or anxiety, although the Cochrane review on the prevention of postnatal depression concluded that this is not effective (6). Evidence on the risk to the fetus of chronic subthreshold anxiety during pregnancy influenced our decision (7).

Dr. Payne gives only limited consideration of psychological therapies, but these are equally effective and safer than medication, particularly in less severe depression (8). We recommended that psychological treatments should be offered without delay in order to avoid the risks associated with antidepressants where this is appropriate (2). The considerable reluctance of many pregnant women to take medication influenced this decision.

Finally, antidepressants are used to treat a range of disorders in addition to depression, particularly anxiety disorders. Psychological treatments are often appropriate in these disorders and should be offered in place of antidepressants where appropriate (2).

Footnotes

Mr. Pilling receives funding from the National Institute for Clinical Excellence for the development of clinical guidelines in mental health. Dr. Tomson has served as chairperson of the Antenatal and Postnatal Mental Health Guideline Development Group, of which Dr. McDonald was a member and to which Ms. Burbeck has provided technical support. Dr. McDonald has received speaker’s honorarium from Janssen-Cilag.

This letter (doi: 10.1176/appi.ajp.2007.07091462) was accepted for publication in October 2007.

References

  1. Payne JL: Antidepressant use in the postpartum period: practical considerations. Am J Psychiatry 2007; 164:1329–1332[Free Full Text]
  2. National Institute for Clinical Excellence: Antenatal and Postnatal Mental Health: Clinical Management and Service Guidance, Clinical Guideline No. 47. London, NICE, 2007
  3. Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, Mitchell AA: Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006; 354:579–587[Abstract/Free Full Text]
  4. National Teratology Information Service: Use of Paroxetine in Pregnancy. Newcastle, Australia, Regional Drug and Therapeutics Centre, NTIS, 2005
  5. Haddad PM, Pal BR, Clarke P, Wieck A, Sridhiran S: Neonatal symptoms following maternal paroxetine treatment: serotonin toxicity or paroxetine discontinuation syndrome? J Psychopharmacol 2005; 19:554–557[Abstract/Free Full Text]
  6. Dennis CL: Psychosocial and psychological interventions for prevention of postnatal depression: systematic review. BMJ 2005; 331:15[Abstract/Free Full Text]
  7. Van den Bergh BR, Mulder EJ, Mennes M, Glover V: Antenatal maternal anxiety and stress and the neurobehavioural development of the fetus and child: links and possible mechanisms (review). Neurosci Biobehav Rev 2005; 29:237–258[CrossRef][Medline]
  8. National Collaborating Centre for Mental Health: Depression: Management of Depression In Primary and Secondary Care. London, Royal College of Psychiatrists and British Psychological Society, 2005




This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by BURBECK, R.
* Articles by McDONALD, L.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by BURBECK, R.
* Articles by McDONALD, L.


Get information about faster international access.

Privacy Policy

Copyright © 2008 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org